D
0913693 B.C. Ltd.
REPCF
$0.002
$0.00015.26%
D
Sell
3/19/2025Downgrade
0913693 B.C. Ltd. (REPCF) was downgraded to D- from D on 3/19/2025 due to a major decline in the efficiency index, total return index and solvency index. Debt to equity increased from -0.25 to -0.16.
0913693 B.C. Ltd. (REPCF) was downgraded to D- from D on 3/19/2025 due to a major decline in the efficiency index, total return index and solvency index. Debt to equity increased from -0.25 to -0.16.
D
Sell
6/14/2024Upgraded
RepliCel Life Sciences Inc. (REPCF) was upgraded to D from D- on 6/14/2024 due to a major increase in the efficiency index and total return index.
RepliCel Life Sciences Inc. (REPCF) was upgraded to D from D- on 6/14/2024 due to a major increase in the efficiency index and total return index.
D
Sell
6/11/2024Upgraded
RepliCel Life Sciences Inc. (REPCF) was upgraded to D- from E+ on 6/11/2024 due to a large increase in the growth index, volatility index and total return index. Operating cash flow increased 266.18% from -$149.3 to $248.1, earnings per share increased from -$0.0099 to $0.0154, and EBIT increased 8.36% from -$242.7 to -$222.4.
RepliCel Life Sciences Inc. (REPCF) was upgraded to D- from E+ on 6/11/2024 due to a large increase in the growth index, volatility index and total return index. Operating cash flow increased 266.18% from -$149.3 to $248.1, earnings per share increased from -$0.0099 to $0.0154, and EBIT increased 8.36% from -$242.7 to -$222.4.
E
Sell
5/22/2024Downgrade
RepliCel Life Sciences Inc. (REPCF) was downgraded to E+ from D- on 5/22/2024 due to a decline in the volatility index.
RepliCel Life Sciences Inc. (REPCF) was downgraded to E+ from D- on 5/22/2024 due to a decline in the volatility index.
D
Sell
5/7/2024Upgraded
RepliCel Life Sciences Inc. (REPCF) was upgraded to D- from E+ on 5/7/2024 due to an increase in the volatility index.
RepliCel Life Sciences Inc. (REPCF) was upgraded to D- from E+ on 5/7/2024 due to an increase in the volatility index.
E
Sell
4/17/2024Downgrade
RepliCel Life Sciences Inc. (REPCF) was downgraded to E+ from D- on 4/17/2024 due to a decline in the volatility index.
RepliCel Life Sciences Inc. (REPCF) was downgraded to E+ from D- on 4/17/2024 due to a decline in the volatility index.
D
Sell
4/1/2024Upgraded
RepliCel Life Sciences Inc. (REPCF) was upgraded to D- from E+ on 4/1/2024 due to an increase in the volatility index.
RepliCel Life Sciences Inc. (REPCF) was upgraded to D- from E+ on 4/1/2024 due to an increase in the volatility index.
E
Sell
3/4/2024Downgrade
RepliCel Life Sciences Inc. (REPCF) was downgraded to E+ from D- on 3/4/2024 due to a decline in the volatility index and total return index.
RepliCel Life Sciences Inc. (REPCF) was downgraded to E+ from D- on 3/4/2024 due to a decline in the volatility index and total return index.
D
Sell
2/15/2024Upgraded
RepliCel Life Sciences Inc. (REPCF) was upgraded to D- from E+ on 2/15/2024 due to an increase in the volatility index.
RepliCel Life Sciences Inc. (REPCF) was upgraded to D- from E+ on 2/15/2024 due to an increase in the volatility index.
E
Sell
1/26/2024Downgrade
RepliCel Life Sciences Inc. (REPCF) was downgraded to E+ from D- on 1/26/2024 due to a decline in the volatility index.
RepliCel Life Sciences Inc. (REPCF) was downgraded to E+ from D- on 1/26/2024 due to a decline in the volatility index.
D
Sell
1/10/2024Upgraded
RepliCel Life Sciences Inc. (REPCF) was upgraded to D- from E+ on 1/10/2024 due to an increase in the valuation index and volatility index.
RepliCel Life Sciences Inc. (REPCF) was upgraded to D- from E+ on 1/10/2024 due to an increase in the valuation index and volatility index.
E
Sell
12/19/2023Downgrade
RepliCel Life Sciences Inc. (REPCF) was downgraded to E+ from D- on 12/19/2023 due to a decline in the valuation index and volatility index.
RepliCel Life Sciences Inc. (REPCF) was downgraded to E+ from D- on 12/19/2023 due to a decline in the valuation index and volatility index.
D
Sell
12/4/2023Upgraded
RepliCel Life Sciences Inc. (REPCF) was upgraded to D- from E+ on 12/4/2023 due to a significant increase in the valuation index and volatility index.
RepliCel Life Sciences Inc. (REPCF) was upgraded to D- from E+ on 12/4/2023 due to a significant increase in the valuation index and volatility index.
E
Sell
11/28/2023Downgrade
RepliCel Life Sciences Inc. (REPCF) was downgraded to E+ from D- on 11/28/2023 due to a decline in the volatility index and total return index.
RepliCel Life Sciences Inc. (REPCF) was downgraded to E+ from D- on 11/28/2023 due to a decline in the volatility index and total return index.
D
Sell
11/10/2023Upgraded
RepliCel Life Sciences Inc. (REPCF) was upgraded to D- from E+ on 11/10/2023 due to an increase in the volatility index.
RepliCel Life Sciences Inc. (REPCF) was upgraded to D- from E+ on 11/10/2023 due to an increase in the volatility index.
E
Sell
10/26/2023Downgrade
RepliCel Life Sciences Inc. (REPCF) was downgraded to E+ from D- on 10/26/2023 due to a decline in the volatility index, total return index and valuation index.
RepliCel Life Sciences Inc. (REPCF) was downgraded to E+ from D- on 10/26/2023 due to a decline in the volatility index, total return index and valuation index.
D
Sell
10/11/2023Upgraded
RepliCel Life Sciences Inc. (REPCF) was upgraded to D- from E+ on 10/11/2023 due to an increase in the volatility index.
RepliCel Life Sciences Inc. (REPCF) was upgraded to D- from E+ on 10/11/2023 due to an increase in the volatility index.
E
Sell
9/26/2023Downgrade
RepliCel Life Sciences Inc. (REPCF) was downgraded to E+ from D- on 9/26/2023 due to a major decline in the growth index, volatility index and valuation index. Operating cash flow declined 367.57% from -$177.3 to -$829, earnings per share declined from $0.0372 to -$0.0137, and EBIT declined 21.02% from -$282.6 to -$342.
RepliCel Life Sciences Inc. (REPCF) was downgraded to E+ from D- on 9/26/2023 due to a major decline in the growth index, volatility index and valuation index. Operating cash flow declined 367.57% from -$177.3 to -$829, earnings per share declined from $0.0372 to -$0.0137, and EBIT declined 21.02% from -$282.6 to -$342.
D
Sell
3/14/2023Downgrade
0913693 B.C. Ltd. (REPCF) was downgraded to D- from D on 03/14/2023.
0913693 B.C. Ltd. (REPCF) was downgraded to D- from D on 03/14/2023.
D
Sell
2/9/2023Upgraded
RepliCel Life Sciences Inc. (REPCF) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index and total return index.
RepliCel Life Sciences Inc. (REPCF) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index and total return index.
E
Sell
2/8/2023Downgrade
RepliCel Life Sciences Inc. (REPCF) was downgraded to E+ from D on 2/8/2023 due to a decline in the volatility index and solvency index. The quick ratio declined from 0.18 to 0.09.
RepliCel Life Sciences Inc. (REPCF) was downgraded to E+ from D on 2/8/2023 due to a decline in the volatility index and solvency index. The quick ratio declined from 0.18 to 0.09.
D
Sell
7/7/2022Upgraded
RepliCel Life Sciences Inc. (REPCF) was upgraded to D from D- on 7/7/2022 due to an increase in the growth index, volatility index and total return index. Operating cash flow increased 36.1% from -$415.5 to -$265.5, EBIT increased 25.52% from -$373 to -$277.8, and earnings per share increased from -$0.0224 to -$0.0178.
RepliCel Life Sciences Inc. (REPCF) was upgraded to D from D- on 7/7/2022 due to an increase in the growth index, volatility index and total return index. Operating cash flow increased 36.1% from -$415.5 to -$265.5, EBIT increased 25.52% from -$373 to -$277.8, and earnings per share increased from -$0.0224 to -$0.0178.
D
Sell
7/6/2022Downgrade
RepliCel Life Sciences Inc. (REPCF) was downgraded to D- from D on 7/6/2022 due to a noticeable decline in the volatility index, growth index and total return index. Operating cash flow declined 44.37% from -$287.8 to -$415.5, and earnings per share declined from -$0.0207 to -$0.0224.
RepliCel Life Sciences Inc. (REPCF) was downgraded to D- from D on 7/6/2022 due to a noticeable decline in the volatility index, growth index and total return index. Operating cash flow declined 44.37% from -$287.8 to -$415.5, and earnings per share declined from -$0.0207 to -$0.0224.
D
Sell
5/5/2022Upgraded
0913693 B.C. Ltd. (REPCF) was upgraded to D from D- on 05/05/2022.
0913693 B.C. Ltd. (REPCF) was upgraded to D from D- on 05/05/2022.
D
Sell
4/20/2022Downgrade
RepliCel Life Sciences Inc. (REPCF) was downgraded to D- from D on 4/20/2022 due to a major decline in the total return index and growth index. Total revenue declined 2.5% from $72 to $70.2.
RepliCel Life Sciences Inc. (REPCF) was downgraded to D- from D on 4/20/2022 due to a major decline in the total return index and growth index. Total revenue declined 2.5% from $72 to $70.2.
D
Sell
11/23/2021Upgraded
RepliCel Life Sciences Inc. (REPCF) was upgraded to D from D- on 11/23/2021 due to an increase in the total return index.
RepliCel Life Sciences Inc. (REPCF) was upgraded to D from D- on 11/23/2021 due to an increase in the total return index.
D
Sell
11/8/2021Downgrade
0913693 B.C. Ltd. (REPCF) was downgraded to D- from D on 11/08/2021.
0913693 B.C. Ltd. (REPCF) was downgraded to D- from D on 11/08/2021.
D
Sell
1/4/2021Upgraded
RepliCel Life Sciences Inc. (REPCF) was upgraded to D from D- on 1/4/2021 due to an increase in the total return index and volatility index.
RepliCel Life Sciences Inc. (REPCF) was upgraded to D from D- on 1/4/2021 due to an increase in the total return index and volatility index.
D
Sell
12/2/2020Downgrade
RepliCel Life Sciences Inc. (REPCF) was downgraded to D- from D on 12/2/2020 due to a substantial decline in the solvency index, total return index and growth index. Operating cash flow declined 1,006.27% from -$59 to -$652.7, EBIT declined 96.63% from -$198.9 to -$391.1, and earnings per share declined from -$0.0084 to -$0.015.
RepliCel Life Sciences Inc. (REPCF) was downgraded to D- from D on 12/2/2020 due to a substantial decline in the solvency index, total return index and growth index. Operating cash flow declined 1,006.27% from -$59 to -$652.7, EBIT declined 96.63% from -$198.9 to -$391.1, and earnings per share declined from -$0.0084 to -$0.015.
D
Sell
5/1/2020Downgrade
RepliCel Life Sciences Inc. (REPCF) was downgraded to D from D+ on 5/1/2020 due to a significant decline in the efficiency index, solvency index and total return index.
RepliCel Life Sciences Inc. (REPCF) was downgraded to D from D+ on 5/1/2020 due to a significant decline in the efficiency index, solvency index and total return index.
D
Sell
3/24/2020Downgrade
RepliCel Life Sciences Inc. (REPCF) was downgraded to D+ from C- on 3/24/2020 due to a decline in the volatility index and total return index.
RepliCel Life Sciences Inc. (REPCF) was downgraded to D+ from C- on 3/24/2020 due to a decline in the volatility index and total return index.
C
Hold
3/9/2020Upgraded
RepliCel Life Sciences Inc. (REPCF) was upgraded to C- from D+ on 3/9/2020 due to an increase in the total return index and volatility index.
RepliCel Life Sciences Inc. (REPCF) was upgraded to C- from D+ on 3/9/2020 due to an increase in the total return index and volatility index.
D
Sell
11/29/2019Upgraded
RepliCel Life Sciences Inc. (REPCF) was upgraded to D+ from D on 11/29/2019 due to a significant increase in the efficiency index, solvency index and growth index. Operating cash flow increased 59.36% from -$667.4 to -$271.2, EBIT increased 39.05% from -$697.8 to -$425.3, and earnings per share increased from -$0.0259 to -$0.0158.
RepliCel Life Sciences Inc. (REPCF) was upgraded to D+ from D on 11/29/2019 due to a significant increase in the efficiency index, solvency index and growth index. Operating cash flow increased 59.36% from -$667.4 to -$271.2, EBIT increased 39.05% from -$697.8 to -$425.3, and earnings per share increased from -$0.0259 to -$0.0158.
D
Sell
5/2/2019Downgrade
RepliCel Life Sciences Inc. (REPCF) was downgraded to D from D+ on 5/2/2019 due to a significant decline in the efficiency index and volatility index. Net income declined 18.08% from -$585.3 to -$691.1.
RepliCel Life Sciences Inc. (REPCF) was downgraded to D from D+ on 5/2/2019 due to a significant decline in the efficiency index and volatility index. Net income declined 18.08% from -$585.3 to -$691.1.
D
Sell
11/26/2018Upgraded
RepliCel Life Sciences Inc. (REPCF) was upgraded to D+ from D on 11/26/2018 due to a significant increase in the efficiency index, total return index and volatility index.
RepliCel Life Sciences Inc. (REPCF) was upgraded to D+ from D on 11/26/2018 due to a significant increase in the efficiency index, total return index and volatility index.
D
Sell
5/11/2018Upgraded
RepliCel Life Sciences Inc. (REPCF) was upgraded to D from D- on 5/11/2018 due to an increase in the growth index. Earnings per share increased from -$0.0509 to -$0.0235, and EBIT increased 52.49% from -$969.2 to -$460.5.
RepliCel Life Sciences Inc. (REPCF) was upgraded to D from D- on 5/11/2018 due to an increase in the growth index. Earnings per share increased from -$0.0509 to -$0.0235, and EBIT increased 52.49% from -$969.2 to -$460.5.
D
Sell
4/25/2018Downgrade
RepliCel Life Sciences Inc. (REPCF) was downgraded to D- from D on 4/25/2018 due to a decline in the volatility index.
RepliCel Life Sciences Inc. (REPCF) was downgraded to D- from D on 4/25/2018 due to a decline in the volatility index.
D
Sell
1/9/2018Upgraded
RepliCel Life Sciences Inc. (REPCF) was upgraded to D from D- on 1/9/2018 due to an increase in the volatility index.
RepliCel Life Sciences Inc. (REPCF) was upgraded to D from D- on 1/9/2018 due to an increase in the volatility index.
D
Sell
12/1/2017Upgraded
RepliCel Life Sciences Inc. (REPCF) was upgraded to D- from E+ on 12/1/2017 due to a large increase in the growth index, valuation index and efficiency index. Operating cash flow increased 74.89% from -$1.66M to -$416.6, earnings per share increased from -$0.0996 to -$0.0509, and net income increased 48.86% from -$1.86M to -$948.8.
RepliCel Life Sciences Inc. (REPCF) was upgraded to D- from E+ on 12/1/2017 due to a large increase in the growth index, valuation index and efficiency index. Operating cash flow increased 74.89% from -$1.66M to -$416.6, earnings per share increased from -$0.0996 to -$0.0509, and net income increased 48.86% from -$1.86M to -$948.8.
E
Sell
8/31/2017Downgrade
RepliCel Life Sciences Inc. (REPCF) was downgraded to E+ from D- on 8/31/2017 due to a noticeable decline in the growth index, solvency index and volatility index. The quick ratio declined from 4.42 to 1.17, EBIT declined 44.41% from -$1.28M to -$1.85M, and earnings per share declined from -$0.0773 to -$0.0996.
RepliCel Life Sciences Inc. (REPCF) was downgraded to E+ from D- on 8/31/2017 due to a noticeable decline in the growth index, solvency index and volatility index. The quick ratio declined from 4.42 to 1.17, EBIT declined 44.41% from -$1.28M to -$1.85M, and earnings per share declined from -$0.0773 to -$0.0996.
D
Sell
6/2/2017Upgraded
RepliCel Life Sciences Inc. (REPCF) was upgraded to D- from E+ on 6/2/2017 due to a noticeable increase in the growth index, solvency index and valuation index. The quick ratio increased from 2.54 to 4.42, earnings per share increased from -$0.1096 to -$0.0773, and operating cash flow increased 22.93% from -$1.84M to -$1.42M.
RepliCel Life Sciences Inc. (REPCF) was upgraded to D- from E+ on 6/2/2017 due to a noticeable increase in the growth index, solvency index and valuation index. The quick ratio increased from 2.54 to 4.42, earnings per share increased from -$0.1096 to -$0.0773, and operating cash flow increased 22.93% from -$1.84M to -$1.42M.
E
Sell
5/19/2017Downgrade
RepliCel Life Sciences Inc. (REPCF) was downgraded to E+ from D- on 5/19/2017 due to a decline in the total return index and volatility index.
RepliCel Life Sciences Inc. (REPCF) was downgraded to E+ from D- on 5/19/2017 due to a decline in the total return index and volatility index.
D
Sell
5/17/2017Downgrade
RepliCel Life Sciences Inc. (REPCF) was downgraded to D- from D+ on 5/17/2017 due to a significant decline in the efficiency index, growth index and valuation index. Operating cash flow declined 2,027.4% from -$86.5 to -$1.84M, EBIT declined 170.96% from -$489 to -$1.33M, and net income declined 165.92% from -$499.4 to -$1.33M.
RepliCel Life Sciences Inc. (REPCF) was downgraded to D- from D+ on 5/17/2017 due to a significant decline in the efficiency index, growth index and valuation index. Operating cash flow declined 2,027.4% from -$86.5 to -$1.84M, EBIT declined 170.96% from -$489 to -$1.33M, and net income declined 165.92% from -$499.4 to -$1.33M.
D
Sell
1/11/2017Upgraded
RepliCel Life Sciences Inc. (REPCF) was upgraded to D+ from D on 1/11/2017 due to an increase in the total return index and volatility index.
RepliCel Life Sciences Inc. (REPCF) was upgraded to D+ from D on 1/11/2017 due to an increase in the total return index and volatility index.
D
Sell
12/1/2016Upgraded
RepliCel Life Sciences Inc. (REPCF) was upgraded to D from D- on 12/1/2016 due to a significant increase in the efficiency index. Net income increased 17.12% from -$603.4 to -$500.1.
RepliCel Life Sciences Inc. (REPCF) was upgraded to D from D- on 12/1/2016 due to a significant increase in the efficiency index. Net income increased 17.12% from -$603.4 to -$500.1.
D
Sell
8/24/2016Downgrade
RepliCel Life Sciences Inc. (REPCD) was downgraded to D- from D on 8/24/2016 due to a decline in the volatility index and total return index.
RepliCel Life Sciences Inc. (REPCD) was downgraded to D- from D on 8/24/2016 due to a decline in the volatility index and total return index.
D
Sell
8/9/2016Upgraded
RepliCel Life Sciences Inc. (REPCF) was upgraded to D from D- on 8/9/2016 due to an increase in the valuation index, volatility index and efficiency index. Net income increased 19.87% from -$973.9 to -$780.4.
RepliCel Life Sciences Inc. (REPCF) was upgraded to D from D- on 8/9/2016 due to an increase in the valuation index, volatility index and efficiency index. Net income increased 19.87% from -$973.9 to -$780.4.
D
Sell
3/11/2016Downgrade
RepliCel Life Sciences Inc. (REPCF) was downgraded to D- from D on 3/11/2016 due to a major decline in the volatility index and total return index.
RepliCel Life Sciences Inc. (REPCF) was downgraded to D- from D on 3/11/2016 due to a major decline in the volatility index and total return index.
D
Sell
1/15/2016Downgrade
RepliCel Life Sciences Inc. (REPCF) was downgraded to D from D+ on 1/15/2016 due to a noticeable decline in the total return index.
RepliCel Life Sciences Inc. (REPCF) was downgraded to D from D+ on 1/15/2016 due to a noticeable decline in the total return index.
D
Sell
12/31/2015Upgraded
RepliCel Life Sciences Inc. (REPCF) was upgraded to D+ from D on 12/31/2015 due to a large increase in the growth index and total return index.
RepliCel Life Sciences Inc. (REPCF) was upgraded to D+ from D on 12/31/2015 due to a large increase in the growth index and total return index.
D
Sell
11/26/2014Downgrade
RepliCel Life Sciences Inc. (REPCF) was downgraded to D from D+ on 11/26/2014 due to a significant decline in the efficiency index, solvency index and growth index. Total capital declined 28.98% from $3.84M to $2.73M, the quick ratio declined from 13.59 to 9.89, and earnings per share declined from -$0.0257 to -$0.0211.
RepliCel Life Sciences Inc. (REPCF) was downgraded to D from D+ on 11/26/2014 due to a significant decline in the efficiency index, solvency index and growth index. Total capital declined 28.98% from $3.84M to $2.73M, the quick ratio declined from 13.59 to 9.89, and earnings per share declined from -$0.0257 to -$0.0211.
D
Sell
4/24/2014Downgrade
RepliCel Life Sciences Inc. (REPCF) was downgraded to D+ from C- on 4/24/2014 due to a large decline in the efficiency index. Net income declined 139.46% from $2.52M to -$993, and total capital declined 44.43% from $2.5M to $1.39M.
RepliCel Life Sciences Inc. (REPCF) was downgraded to D+ from C- on 4/24/2014 due to a large decline in the efficiency index. Net income declined 139.46% from $2.52M to -$993, and total capital declined 44.43% from $2.5M to $1.39M.
OTC PK
02/19/2025 12:43PM Eastern
Quotes delayed
